Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nutriband Inc. (NTRB)
USD3.05
+0.07 (+2.35%)
US NASDAQ Healthcare Biotechnology
Address
121 South Orange Avenue 32801
Orlando, FL, US
Orlando, FL, US
CEO
Gareth Sheridan
Website
nutriband.com
IPO
2021-10-01
CIK 1676047 ISIN US67092M2089
Also trades on
NASDAQ Capital Market · NTRB (USD)
NASDAQ Capital Market · NTRBW (USD)
Description
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.05
+0.07 (+2.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10.7K
Beta
1.93
Float Shares
5.25M
Free Float %
43.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.23% | -2.22% | -3.56% | -10.66% | -29.18% | -22.47% | -53.68% | +28.47% | -38.68% | -38.68% | -38.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
3.05
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
15.69
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-4.8% Q2'26: -35.1% (vs Q2'25)
-
EPS growth Biotechnology: +29.7%-160.6% Q2'26: +16.7% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-394.0% Q2'26: -129.9% (vs Q2'25)
-
EBIT margin Biotechnology: +0.0%-408.4% Q2'26: +0.0% (vs Q2'25)
-
ROIC Biotechnology: -16.1%-359.4% Q2'26: +0.0% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+9.8% Q2'26: +9.3% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q2'26: -0.04× (vs Q2'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jan 2019 actual |
Jan 2020 actual |
Jan 2021 actual |
Jan 2022 actual |
Jan 2023 actual |
Jan 2024 actual |
Jan 2025 actual |
Jan 2026 1 Rev. Ana. 1 EPS Ana. |
Jan 2027 1 Rev. Ana. 1 EPS Ana. |
Jan 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
245.3K
est: 762.8K (-67.8%)
|
370.6K
est: 451.1K (-17.8%)
|
943.7K
est: 1.06M (-11.0%)
|
1.42M
est: 1.39M (+2.6%)
|
2.08M
est: 2.20M (-5.5%)
|
2.09M
est: 3.30M (-36.8%)
|
2.14M
est: 2.30M (-6.8%)
|
2.73M
2.73M – 2.73M
+18.9% YoY
|
95.41M
95.41M – 95.41M
+3,394.9% YoY
|
180.41M
180.41M – 180.41M
+89.1% YoY
|
| EBITDA |
-3.29M
est: -762.8K (-331.9%)
|
-2.56M
est: -451.1K (-466.7%)
|
-2.48M
est: -1.06M (-134.1%)
|
-5.74M
est: -1.39M (-314.1%)
|
-4.11M
est: -2.20M (-86.6%)
|
-5.12M
est: -3.30M (-55.2%)
|
-10.18M
est: -2.30M (-343.0%)
|
-2.73M
-2.73M – -2.73M
-18.9% YoY
|
-95.41M
-95.41M – -95.41M
-3,394.9% YoY
|
-180.41M
-180.41M – -180.41M
-89.1% YoY
|
| EBIT |
-3.33M
est: -762.8K (-336.7%)
|
-2.65M
est: -451.1K (-487.1%)
|
-2.65M
est: -1.06M (-150.1%)
|
-6.06M
est: -1.39M (-337.1%)
|
-4.48M
est: -2.20M (-103.4%)
|
-5.41M
est: -3.30M (-63.9%)
|
-10.46M
est: -2.30M (-355.4%)
|
-2.73M
-2.73M – -2.73M
-18.9% YoY
|
-95.41M
-95.41M – -95.41M
-3,394.9% YoY
|
-180.41M
-180.41M – -180.41M
-89.1% YoY
|
| Net Income |
-3.33M
est: -4.36M (+23.7%)
|
-2.80M
est: -3.09M (+9.6%)
|
-3.21M
est: -1.09M (-194.5%)
|
-8.42M
est: -6.23M (-35.2%)
|
-4.81M
est: -4.14M (-16.3%)
|
-5.49M
est: -2.44M (-124.8%)
|
-10.48M
est: -11.52M (+9.0%)
|
-72.17M
-72.17M – -72.17M
-526.3% YoY
|
18.28M
18.28M – 18.28M
+125.3% YoY
|
42.61M
42.61M – 42.61M
+133.1% YoY
|
| SGA |
3.29M
est: 1.78M (+85.0%)
|
1.79M
est: 1.05M (+70.4%)
|
2.96M
est: 2.47M (+19.7%)
|
4.02M
est: 3.23M (+24.6%)
|
3.92M
est: 5.13M (-23.6%)
|
3.77M
est: 7.69M (-50.9%)
|
4.27M
est: 5.48M (-22.1%)
|
6.51M
6.51M – 6.51M
+18.9% YoY
|
227.63M
227.63M – 227.63M
+3,394.9% YoY
|
430.43M
430.43M – 430.43M
+89.1% YoY
|
| EPS |
-0.53
est: -0.41 (-28.8%)
|
-0.44
est: -0.29 (-51.0%)
|
-0.48
est: -0.10 (-366.7%)
|
-1.06
est: -0.59 (-80.5%)
|
-0.57
est: -0.39 (-46.2%)
|
-0.69
est: -0.23 (-200.0%)
|
-0.99
est: -0.99 (+0.0%)
|
-6.20
-6.20 – -6.20
-526.3% YoY
|
1.57
1.57 – 1.57
+125.3% YoY
|
3.66
3.66 – 3.66
+133.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-10 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-09 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-03 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-02 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.64M
OE per share TTM
-0.39
Owner's Yield
-10.84%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
47.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
19
Total invested
1.65M
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VITALE BOTGROS | 4.18M | 32.37% | — | 2.37M | — | 4.18M | IN | Cyprus | 2024-09-19 | ↗ |
| 2 | NOCIATA HOLDING LIMITED | 4.18M | 32.00% | — | 2.37M | — | 4.18M | CO | Cyprus | 2024-09-19 | ↗ |
| 3 | Gareth Sheridan | 2.01M | 17.73% | 1.76M | — | 1.76M | — | IN | UNITED STATES | 2025-03-13 | ↗ |
| 4 | T.I.I. - JETSERVICES, LDA | 1.87M | 16.06% | — | 1.32M | — | 1.87M | CO | Portugal | 2024-09-19 | ↗ |
| 5 | Serguei Melnik | 1.07M | 9.39% | 820.4K | — | 820.4K | — | IN | UNITED STATES | 2025-03-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
19
+0 vs prev Q
New positions
3
Closed positions
3
Increased
4
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 202.7K +— (+0.0%) | 920.4K -508.9K (-35.6%) | 1.68% -0.126 pp | 0.00% +0.000 pp | USD4.91 -7.5% | 16 qtrs — |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 59.9K +— (+0.0%) | 272.2K -150.5K (-35.6%) | 0.50% -0.037 pp | 0.00% +0.000 pp | USD4.10 +10.7% | 16 qtrs — |
| 3 | STATE STREET CORP | 25.0K +— (+0.0%) | 113.3K -62.7K (-35.6%) | 0.21% -0.016 pp | 0.00% +0.000 pp | USD4.92 -7.7% | 16 qtrs — |
| 4 | — | 16.0K +16.0K (+100.0%) | 72.7K +72.7K (+100.0%) | 0.13% +0.133 pp | 0.06% +0.055 pp | USD4.54 +0.0% | 1 qtrs NEW |
| 5 | NORTHERN TRUST CORP | 13.9K +— (+0.0%) | 63.3K -35.0K (-35.6%) | 0.12% -0.009 pp | 0.00% +0.000 pp | USD6.29 -27.8% | 4 qtrs — |
| 6 | HAVEN PRIVATE, LLC | 11.4K -95.0 (-0.8%) | 51.9K -29.3K (-36.1%) | 0.09% -0.008 pp | 0.02% -0.013 pp | USD4.71 -3.6% | 5 qtrs — |
| 7 | CETERA INVESTMENT ADVISERS | 11.4K -7.5K (-39.7%) | 51.8K -81.5K (-61.2%) | 0.09% -0.074 pp | 0.00% 0.000 pp | USD7.05 -35.6% | 2 qtrs — |
| 8 | BLACKROCK, INC. | 8.8K +354.0 (+4.2%) | 39.8K -19.5K (-32.9%) | 0.07% -0.002 pp | 0.00% +0.000 pp | USD7.72 -41.2% | 3 qtrs — |
| 9 | ADVISOR GROUP HOLDINGS, INC. | 4.9K +— (+0.0%) | 22.0K -10.3K (-32.0%) | 0.04% -0.003 pp | 0.00% +0.000 pp | USD3.86 +17.6% | 16 qtrs — |
| 10 | MORGAN STANLEY | 3.5K +— (+0.0%) | 15.9K -8.8K (-35.6%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD6.13 -25.9% | 4 qtrs — |
| 11 | WELLS FARGO & COMPANY/MN | 2.6K +— (+0.0%) | 11.8K -6.5K (-35.6%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD6.09 -25.5% | 13 qtrs — |
| 12 | UBS GROUP AG | 1.2K -18.4K (-93.6%) | 5.7K -132.8K (-95.9%) | 0.01% -0.165 pp | 0.00% +0.000 pp | USD7.05 -35.6% | 17 qtrs — |
| 13 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.1K +1.1K (+100.0%) | 5.1K +5.1K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD4.54 +0.0% | 1 qtrs NEW |
| 14 | CITIGROUP INC | 656.00 -604.0 (-47.9%) | 3.0K -5.9K (-66.5%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD7.05 -35.6% | 4 qtrs — |
| 15 | JONES FINANCIAL COMPANIES LLLP | 584.00 -182.0 (-23.8%) | 2.7K -2.9K (-52.3%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD6.69 -32.1% | 7 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 106.00 -92.0 (-46.5%) | 481.00 -915.0 (-65.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD7.50 -39.5% | 9 qtrs — |
| 17 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 4.00 +4.0 (+100.0%) | 18.00 +18.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.50 +0.9% | 1 qtrs NEW |
| 18 | HARBOUR INVESTMENTS, INC. | 3.00 +— (+0.0%) | 14.00 -7.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.67 -40.8% | 3 qtrs — |
| 19 | SBI SECURITIES CO., LTD. | 2.00 +— (+0.0%) | 9.00 -5.0 (-35.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.50 -39.5% | 3 qtrs — |
| 20 | BARCLAYS PLC | — -18.0 (-100.0%) | — -127.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 21 | ROYAL BANK OF CANADA | — -300.0 (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 22 | CLEAR STREET GROUP INC. | — -1.0 (-100.0%) | — -7.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.00% | 29.5K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 178.5K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 906.87 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.5K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 183.92 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 425.5K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 932.50 | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 507.54 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 205.17 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 22.57 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
5.0K
Cash buys
—
Cash sales
—
Net activity
-5,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-31 | Sheridan Gareth | Director / Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,761,667 | D | ↗ |
| 2025-01-29 | Sheridan Gareth | Director / Officer / 10% Owner | A-Award | A | Stock Option | 29,333 | 8.07 | 236.7K | 251,000 | D | ↗ |
| 2025-01-23 | Goodman Gerald | Officer | A-Award | A | Stock Option | 17,667 | 7.34 | 129.7K | 185,500 | D | ↗ |
| 2024-06-06 | Goodman Gerald | Officer | M-Exempt | A | Stock Warrant | 87,500 | 1.93 | 168.9K | 179,500 | D | ↗ |
| 2024-06-05 | Goodman Gerald | Officer | X-InTheMoney | D | Warrant | 60,085 | 1.93 | 116.0K | 60,085 | D | ↗ |
| 2024-03-20 | Sheridan Gareth | Director / Officer / 10% Owner | A-Award | A | Stock Option | 97,500 | 2.61 | 254.5K | 251,000 | D | ↗ |
| 2024-03-20 | MELNIK SERGUEI | Director / Officer | A-Award | A | Options to Purchase Common Stock | 97,500 | 2.61 | 254.5K | 245,000 | D | ↗ |
| 2024-03-20 | Goodman Gerald | Officer | A-Award | A | Stock Option | 75,000 | 2.37 | 177.8K | 267,000 | D | ↗ |
| 2024-03-19 | Goodman Gerald | Officer | A-Award | A | Stock Option | 75,000 | 1.93 | 144.8K | 75,000 | D | ↗ |
| 2023-10-27 | Goodman Gerald | Officer | A-Award | A | Stock Option | 49,500 | 1.93 | 95.5K | 192,000 | — | ↗ |
| 2023-03-06 | MELNIK SERGUEI | Director / Officer / 10% Owner | G-Gift | D | Common Stock, par value $0.001 per share | 5,000 | 0.00 | — | 827,999 | — | ↗ |
| 2022-12-09 | Goodman Gerald | Officer | A-Award | A | Stock Option | 20,000 | 3.53 | 70.6K | 142,500 | — | ↗ |
| 2022-08-16 | Goodman Gerald | Officer | A-Award | A | Stock Option | 23,333 | 4.09 | 95.4K | 23,333 | — | ↗ |
| 2022-05-10 | Sheridan Gareth | Officer | A-Award | A | Common Stock | 10,000 | 3.80 | 38.0K | 1,520,000 | — | ↗ |
| 2022-02-24 | MELNIK SERGUEI | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 per share | 500 | 4.03 | 2.0K | 633,000 | — | ↗ |
| 2022-02-06 | MELNIK SERGUEI | Director / Officer | G-Gift | D | Common Stock, par value $0.001 per share | 10,000 | 0.00 | — | 632,500 | — | ↗ |
| 2022-01-21 | Sheridan Gareth | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 20,000 | 5.34 | 106.8K | 20,000 | — | ↗ |
| 2022-01-21 | MELNIK SERGUEI | Director / Officer | A-Award | A | Options to Purchase Common Stock | 20,000 | 5.34 | 106.8K | 20,000 | — | ↗ |
| 2022-01-21 | Goodman Gerald | Officer | A-Award | A | Stock Option | 11,167 | 4.16 | 46.5K | 98,667 | — | ↗ |
| 2021-10-22 | Goodman Gerald | Officer | A-Award | A | CS Purchase Warrant | 87,500 | 1.93 | 168.9K | 87,500 | — | ↗ |
| 2021-01-31 | Sheridan Gareth | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-30 | MELNIK SERGUEI | Director / Officer | G-Gift | D | Common Stock, par value $0.001 per share | 20,000 | 0.00 | — | 2,530,000 | — | ↗ |
| 2018-07-31 | Davidov Michael | Director | A-Award | A | Common Stock, par value $0.001 per share | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2018-05-31 | Davidov Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-31 | Sheridan Gareth | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-31 | MELNIK SERGUEI | Director / Officer / 10% Owner | — | D | Common Stock, par value $0. 001 per share | 0 | 0.00 | — | 2,550,000 | — | ↗ |
| 2017-08-19 | MELNIK SERGUEI | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 450,000 | 0.00 | 450.00 | 2,550,000 | — | ↗ |
| 2017-08-17 | Sheridan Gareth | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 1,000,000 | 0.00 | 1.0K | 6,000,000 | — | ↗ |
| 2017-01-31 | Sheridan Gareth | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-31 | MELNIK SERGUEI | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-01-31 | Botgros Vitalie | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.4K
Shares Outstanding
12.16M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gareth Sheridan, CEO | 150.0K | — | — | 203.4K | — | 5.0K | 358.4K | 56.75% | ↗ |
| 2 | 2025 | Serguei Melnik President | 150.0K | — | — | 203.4K | — | 5.0K | 358.4K | 56.75% | ↗ |
| 3 | 2025 | Alan Smith Chief Operating Officer | 154.0K | — | — | 142.0K | — | 5.0K | 301.0K | 47.18% | ↗ |
| 4 | 2025 | Gerald Goodman Chief Financial Officer | 110.0K | — | — | 147.6K | — | 5.0K | 262.6K | 56.20% | ↗ |
| 5 | 2024 | Gareth Sheridan, CEO | 150.0K | — | 38.0K | 82.1K | — | 25.0K | 285.1K | 42.13% | ↗ |
| 6 | 2024 | Serguei Melnik President | 150.0K | — | — | 82.1K | — | 25.0K | 257.1K | 31.94% | ↗ |
| 7 | 2024 | Alan Smith Chief Operating Officer | 154.0K | — | — | 42.7K | — | 5.0K | 201.7K | 21.18% | ↗ |
| 8 | 2024 | Gerald Goodman Chief Financial Officer | 110.0K | — | — | 52.9K | — | 30.0K | 192.9K | 27.41% | ↗ |
| 9 | 2023 | Gareth Sheridan, CEO | 200.0K | — | 38.0K | 140.7K | — | — | 378.7K | 47.18% | ↗ |
| 10 | 2023 | Serguei Melnik President | 200.0K | — | — | 146.7K | — | — | 346.7K | 42.31% | ↗ |
| 11 | 2023 | Gerald Goodman Chief Financial Officer | 160.0K | — | — | 115.0K | — | — | 275.0K | 41.81% | ↗ |
| 12 | 2023 | Alan Smith Chief Operating Officer | 179.0K | — | — | 57.5K | — | — | 236.5K | 24.31% | ↗ |
| 13 | 2022 | Serguei Melnik President | 149.0K | 100.0K | — | 61.8K | — | — | 310.8K | 19.88% | ↗ |
| 14 | 2022 | Gareth Sheridan, CEO | 149.0K | 100.0K | — | 61.8K | — | — | 310.8K | 19.88% | ↗ |
| 15 | 2022 | Alan Smith Chief Operating Officer Sean Gallagher, Executive Chairman | 148.0K | — | — | 32.7K | — | — | 264.7K | 12.34% | ↗ |
| 16 | 2022 | Alan Smith Chief Operating Officer | 148.0K | — | — | 32.7K | — | — | 264.7K | 12.34% | ↗ |
| 17 | 2022 | Gerald Goodman Chief Financial Officer | 120.1K | — | — | 32.7K | — | — | 152.8K | 21.37% | ↗ |
| 18 | 2021 | Gareth Sheridan, CEO | 60.0K | — | 150.0K | — | — | — | 210.0K | 71.43% | ↗ |
| 19 | 2021 | Sean Gallagher, Executive Chairman | — | — | 150.0K | — | — | — | 150.0K | 100.00% | ↗ |
| 20 | 2021 | Alan Smith Chief Operating Officer Sean Gallagher, Executive Chairman | — | — | 150.0K | — | — | — | 150.0K | 100.00% | ↗ |
| 21 | 2020 | Jeff Patrick Chief Scientific Officer | — | — | 60.0K | — | 252.7K | — | 312.7K | 19.19% | ↗ |
| 22 | 2020 | Sean Gallagher, Executive Chairman | — | — | 60.0K | — | — | — | 60.0K | 100.00% | ↗ |
| 23 | 2020 | Alan Smith Chief Operating Officer Sean Gallagher, Executive Chairman | — | — | 60.0K | — | — | — | 60.0K | 100.00% | ↗ |
| 24 | 2020 | Gareth Sheridan, CEO | 42.0K | 15.0K | — | — | — | — | 57.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Serguei Melnik | Founder, President, Company Secretary & Executive Chairman | 542.1K | male |
| Gareth Sheridan | Founder, Chief Executive Officer & Director | 542.1K | male |
| Alan Smith | Chief Operating Officer & President of 4P Therapeutics | 161.7K | — |
| Gerald Goodman | Chief Financial Officer & Chief Accounting Officer | 147.7K | male |
| Michael Myer | President of Pocono Pharmaceutical | 40.6K | male |
| Jeffrey Patrick | Chief Scientific Officer | — | — |
| Tyler Overk | Head of Active Intelligence | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NTRB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
